A small, exploratory 2026 trial published in the New England Journal of Medicine tested an optogenetic therapy for advanced retinitis pigmentosa, a disease in which the retina's light-detecting photoreceptors deteriorate. Researchers injected a viral vector carrying a light-sensitive channel gene into retinal ganglion cells, the retina's output neurons, bypassing the damaged photoreceptors and middle retinal circuitry entirely. Because ganglion cells normally receive pre-processed signals rather than raw light, patients wore goggles that converted the visual scene into a simplified format, such as edge detection, before projecting it into the treated eye. The study of 10 participants was open-label and designed primarily to test safety, with a secondary aim of measuring whether light sensitivity improved.
- 01
Both of each patient's eyes were profoundly visually impaired to begin with; only the worse-seeing eye received the injection, and the untreated eye was patched during testing rather than serving as a normal-vision control.
- 02
Edge detection is only one of many computations the retina normally performs; ganglion cells include specialized types for motion and on-off responses, so the goggles' preprocessing is described as a crude approximation of the eye's natural circuitry.
- 03
The channelrhodopsin protein used in the therapy was originally identified in algae by Peter Hegemann, one of the scientists honored in the related Nobel Prize for optogenetics.
- 04
The hosts contrast this approach with an earlier-discussed therapy, the Prima system, which restores vision using an implanted chip responding to infrared light rather than gene therapy.
ChemistryNeuroscienceNobel PrizeParticle PhysicsAstrobiology